Imagine being told that a life-saving treatment exists, but it’s not available to you simply because of where you live. This is the harsh reality thousands of men in England have faced—until now. A groundbreaking prostate cancer drug, abiraterone, is finally set to be offered to thousands in England, marking a monumental shift in the fight against this devastating disease. But here’s where it gets controversial: despite its proven benefits, this drug has been available in Scotland and Wales since 2023, leaving English patients in the lurch. Why the delay? And what does this mean for those who’ve been fighting for access?
Abiraterone, a drug that halts the spread of prostate cancer by depriving it of the hormones it needs to grow, has been a lifeline for patients with advanced stages of the disease. Until now, it was only prescribed in England and Northern Ireland for the most severe cases. But in a matter of weeks, high-risk patients whose cancer hasn’t yet metastasized will gain access through the NHS—a move that could save hundreds of lives annually. This decision comes after a tireless campaign led by a patient, Giles Turner, and the charity Prostate Cancer UK, who argued that the drug’s benefits far outweigh the costs.
Amy Rylance, assistant director of health improvement at Prostate Cancer UK, hailed the decision as a “life-saving victory” for the thousands of men who will now have a fighting chance. She credited the BBC for keeping the issue in the spotlight, ensuring it wasn’t forgotten. The charity estimates that 7,000 men will start treatment each year, with approximately 1,470 avoiding the devastating news that their cancer has worsened. Even more strikingly, around 560 lives are expected to be saved annually.
But this is the part most people miss: the journey to this point has been fraught with frustration. Giles Turner, diagnosed with aggressive prostate cancer in March 2023, was outraged to discover that his postcode determined his access to treatment. While Scotland and Wales had already made abiraterone available, England lagged behind. Turner, who paid £250 a month for the drug, felt fortunate but deeply angered for those who couldn’t afford it. His campaign for policy change began in earnest, yet it took nearly three years for action to be taken. Why did it take so long? And could lives have been saved sooner?
The delay was partly due to bureaucratic hurdles. For the National Institute for Health and Care Excellence (NICE) and the Medicines and Healthcare products Regulatory Agency (MHRA) to approve extended use of the drug, detailed and time-consuming applications are required. Additionally, abiraterone went off-patent in October 2022, meaning other companies could produce generic versions. With no financial incentive for pharmaceutical companies to push for broader approval, the process stalled. Meanwhile, Scotland and Wales found ways to supply the drug within existing protocols, leaving England’s inaction all the more puzzling.
NHS England has now stated that savings from other medicines have made it possible to fund the drug’s expanded availability. Prof Peter Johnson, national clinical director for cancer at NHS England, celebrated the move, saying it will give thousands of men a better chance at longer, healthier lives. Health Secretary Wes Streeting echoed this sentiment, emphasizing the precious extra years the drug can provide. But the question remains: could this have happened sooner?
The evidence supporting abiraterone’s effectiveness is undeniable. The STAMPEDE trial, published in 2022, found that the drug significantly improved survival rates when given alongside standard care. The Institute of Cancer Research noted that two years of treatment halved the risk of cancer recurrence and reduced the risk of death by 40%. Yet, despite this, NICE initially declined to approve its use for newly diagnosed patients. Why was such a life-saving treatment held back?
Now, as NHS England prepares to roll out the treatment, Prostate Cancer UK is pushing for Northern Ireland to follow suit. The charity is urging politicians in Stormont to act swiftly, ensuring no more lives are lost due to geographical disparities. But this raises a broader question: how can we ensure equitable access to life-saving treatments across the UK, regardless of postcode?
This victory is a testament to the power of advocacy and persistence, but it also highlights the flaws in a system that allows such disparities to exist. As we celebrate this progress, let’s not forget the lives that could have been saved sooner. Is it fair that access to life-saving treatments depends on where you live? And what more can be done to prevent such delays in the future? Share your thoughts in the comments—this conversation is far from over.
